Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Smoking cessation, moderate drinking, a healthy diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer.
Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.
Women with a history of the malignancy also survive longer than men after receiving a liver transplant.
Successful treatment with direct-acting antivirals prolonged survival by 18 months.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.
A new classification system may more accurately reflect liver-related death trends in the United States.
Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.
People with liver cirrhosis often have substantial financial burden that interferes with their care.
The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.